Get started
Author

Louis M. Sloan

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
2017 · David A Margolis, Juan Gonzalez-Garcia, et al. · The Lancet · 513
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
2014 · A. Castagna, F. Maggiolo, et al. · The Journal of Infectious Diseases · 336
PDF
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
2011 · Sherene Min, Louis Sloan, et al. · AIDS · 232
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
2009 · Kimberly Y Smith, Parul Patel, et al. · AIDS · 226
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
2018 · Jean-Michel Molina, Kathleen Squires, et al. · The Lancet HIV · 153
Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
2009 · Edwin DeJesus, Benjamin Young, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 136
Dendritic cell‐based therapeutic vaccine elicits polyfunctional HIV‐specific T‐cell immunity associated with control of viral load
2014 · Yves Lévy, Rodolphe Thiébaut, et al. · European Journal of Immunology · 127
PDF
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
2017 · Catherine Orrell, Debbie P Hagins, et al. · The Lancet HIV · 122
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine
2010 · Amanda Cobb, Lee K. Roberts, et al. · Journal of Immunological Methods · 54
Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells
2013 · Anne-Laure Flamar, Yaming Xue, et al. · AIDS · 51
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
2023 · Chloe Orkin, Jean-Michel Molina, et al. · The Lancet HIV · 36
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
2017 · Pedro Cahn, Richard Kaplan, et al. · The Lancet HIV · 35
PDF
Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study
2008 · the ASCENT study team, Judith Currier, et al. · Antiviral Therapy · 25
PDF
Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES
2012 · Benjamin Young, Kathleen E. Squires, et al. · AIDS Research and Human Retroviruses · 22
Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758
2009 · Charles B. Hicks, Edwin DeJesus, et al. · AIDS Research and Human Retroviruses · 21
Central Nervous System Tuberculosis
2010 · Vincent C. Kuo, Louis M. Sloan, et al. · Baylor University Medical Center Proceedings · 18
Clinical and Morphologic Findings in Disseminated Scedosporium Apiospermum Infections in Immunocompromised Patients
2014 · Molly M. Campa-Thompson, James A. West, et al. · Baylor University Medical Center Proceedings · 17
PDF
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
2013 · for the SUPPORT Study Team, Princy Kumar, et al. · BMC Infectious Diseases · 17
PDF
Short Communication: Comparable Safety and Efficacy with Once-Daily Versus Twice-Daily Dosing of Lopinavir/Ritonavir Tablets with Emtricitabine + Tenofovir DF in Antiretroviral-Naïve, HIV Type 1-Infected Subjects: 96 Week Final Results of the Randomized Trial M05-730
2010 · Juan González-García, Daniel Cohen, et al. · AIDS Research and Human Retroviruses · 17
Patients Experiencing Early Virologic Failure on a Protease Inhibitor- or Nonnucleoside Reverse Transcriptase Inhibitor-Based Initial Regimen Containing a Thymidine Analogue and Lamivudine Can Be Successfully Treated With a Quadruple-Nucleoside Regimen
2005 · Allan Rodriguez, Christina Hill-Zabala, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 6
Herpes Simplex Virus Meningitis Complicated by Ascending Paralysis
2013 · Mina M. Benjamin, Kyle L. Gummelt, et al. · Baylor University Medical Center Proceedings · 5
Primary Effusion Lymphoma Diagnosed by Pericardiocentesis
2009 · Michael C. Nemunaitis, Jeffrey M. Schussler, et al. · Baylor University Medical Center Proceedings · 4
P19-45. Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens
2009 · AJ Cobb, H Mead, et al. · Retrovirology · 2
PDF
Comparable Safety and Effi cacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730
2009 · Dani Cohen, Juan González‐García, et al. · 2
HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa
2016 · Adam J. Ericsen, Michael Lauck, et al. · 1
Works count: 36
Citation count: 2,181
H-index: 17
I10-index: 19
Year
Topic
Type